MRK ▲ +0.0% - Merck & Co., Inc.
$MRK - Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan
Merck received approval in Japan for a subcutaneous formulation of its cancer immunotherapy KEYTRUDA, expanding treatment options beyond the currently approved intravenous administration across all approved indications in the country. The subcutaneous version, marketed as KEYTRUDA QLEX, offers patients a more convenient alternative that could broaden accessibility and potentially drive future uptake in one of the world's largest pharmaceutical markets.
21-SEP-2026 06:54 AM ET
Share this post
More filings for $MRK
MRK ▲ +0.4% - Merck & Co., Inc.Nov 20, 2026MRK ▼ -0.3% - Merck & Co., Inc.Nov 19, 2026MRK ▼ -0.3% - Merck & Co., Inc.Nov 19, 2026MRK ▼ -0.6% - Merck & Co., Inc.Nov 17, 2026MRK ▼ -0.6% - Merck & Co., Inc.Nov 17, 2026MRK ▲ +1.2% - Merck & Co., Inc.Nov 9, 2026
View full $MRK filing history →💬 Comments
Loading comments…
Leave a comment
